Stock listing

OTC:BEIGF BeOne Medicines Ltd. Stock

US listing (OTC) of BeOne Medicines Ltd. · home listing Shanghai:688235

Follow BeOne Medicines Ltd. into a list and get an email when it puts out news.

Home listing price · SSE:688235

¥259.37 CNY +3.39 (+1.3%)

Delayed at least 15 minutes · 3:00 PM GMT+8, Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, SSE:688235

Past year -6.8% · daily closes, Oct 20, 2025 – Oct 16, 2026, adjusted for splits
Day range so far
¥253.00 – ¥261.84 CNYDelayed at least 15 minutes · 3:00 PM GMT+8, Oct 19, 2026
Volume
2.82M sharesDelayed at least 15 minutes · 3:00 PM GMT+8, Oct 19, 2026
Market value
¥29.84B CNYDelayed at least 15 minutes · 3:00 PM GMT+8, Oct 19, 2026 · price × 115.1M shares outstanding
52-week range
¥205.51 – ¥319.24 CNYLowest and highest trades, Oct 20, 2025 – Oct 19, 2026
BeOne Medicines Ltd. logo
Ticker
OTC:BEIGF
Asset type
Stock
Exchange
OTC
Currency
USD

What changed lately

Calls

Replays

  • BeOne Medicines (Shanghai:688235) Q2 2026 Earnings Call

    Wed, Aug 05, 2026 · 8:00 AM ET

    Watch Transcript

  • BeOne Medicines (Shanghai:688235) Q1 2026 Earnings Call

    Wed, May 06, 2026 · 8:00 AM ET

    Watch Transcript

  • BeOne Medicines (Shanghai:688235) Q4 2025 Earnings Call

    Thu, Feb 26, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Semi-annual Report for 2026

Aug 27, 2026

Announcement on Convening the 2026 Semi-annual Performance Briefing

Aug 21, 2026

Announcement on Voluntary Disclosure of Adjustment of Operating Performance Forecast for 2026

Aug 6, 2026

Announcement on Voluntary Disclosure of Holding Conference Call for Company Performance

Jul 18, 2026

Grant of Restricted Share Units

Jul 9, 2026

Voluntary Announcement on Progress of Clinical Trial of BRUKINSA (Zanubrutinib Capsules)

Jul 1, 2026

Announcement on the Handling of Relevant Tax Matters

Jun 27, 2026

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale

Jun 2, 2026

BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma

May 13, 2026

Report for Q1 2026

May 12, 2026

All BeOne Medicines Ltd. news

Decks

BeOne Medicines Ltd. on 6ix

News releases
34 in the last 12 months · 107 in all · newest Aug 27, 2026 · oldest 2023
Calls
7 calls with a replay · 7 with a transcript · latest Aug 5, 2026
Decks
21 decks · latest Aug 5, 2026

Where BeOne Medicines Ltd. is listed

ListingExchangeCountryCurrency
Shanghai:688235 百济神州 · Home listingShanghaiChinaCNY
NASDAQ:ONCNASDAQUnited StatesUSD
HKEX:6160 百濟神州HKEXHong KongHKD
gettex:A41ANKgettexGermanyEUR
gettex:49BAgettexGermanyEUR
BMV:6160NBMVMexicoMXN
LS Exchange:A1437NLS ExchangeGermanyEUR
BOATS:ONCBOATSUnited StatesUSD
Lang & Schwarz:A41ANKLang & SchwarzGermanyEUR
OTC:BEIGF · This pageOTCUnited StatesUSD
B3:B1ME34B3BrazilBRL
Tradegate:IJ0TradegateGermanyEUR
BMV:ONCNBMVMexicoMXN
Tradegate:49BATradegateGermanyEUR
Turquoise:ONCNTurquoiseUnited KingdomUSD
Dusseldorf:49BADusseldorfGermanyEUR
Frankfurt:49BAFrankfurtGermanyEUR
Lang & Schwarz:A1437NLang & SchwarzGermanyEUR
Munich:49BAMunichGermanyEUR
Stuttgart:49BAStuttgartGermanyEUR
Stuttgart:IJ0StuttgartGermanyEUR

Log in to ask 6ix AI your own questions about BeOne Medicines Ltd.